Company intelligence / Profile preview
Danube Pharmaceuticals
New York City or n.a., New York, United Stateseinsteinmed.edu ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Danube Pharmaceuticals was a privately held biopharmaceutical company founded in 2005, focused on developing small molecule therapeutics. Its lead candidate, DNB-001, was an oral SUR agonist developed for glaucoma and later explored for myocardial ischemia and kidney injury. The company advanced DNB-001 to Phase 2 clinical trials but is now out of business/discontinued its programs.
- Therapeutic areas
- OphthalmologyCardiovascularNephrology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Danube Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Danube Pharmaceuticals.